Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘Looms Large’

While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.